Safety and usefulness of parenteral iron in the management of anemia due to hip fracture in the elderly

• Published in: Medicina clínica Vol. 123; no. 8; p. 281
• Main Authors: Cuenca Espiérrez, Jorge, García Erce, José Antonio, Martínez Martín, Angel A, Solano, Víctor Manuel, Modrego Aranda, Francisco Javier
• Format: Journal Article
• Language: Spanish
• Published: Spain 11-09-2004
• Subjects: Aged; Aged, 80 and over; Anemia - etiology; Anemia - prevention & control; Blood Loss, Surgical; Blood Transfusion; Female; Ferric Compounds - administration & dosage; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics - administration & dosage; Hip Fractures - surgery; Humans; Infusions, Intravenous; Iron - administration & dosage; Male; Sucrose - administration & dosage
• DOI: 10.1016/S0025-7753(04)74493-0
• ISSN: 0025-7753

An important percentage of patients with hip fracture need allogeneic transfusion to resolve their perioperative anemia. Our goal was to determine the safety profile and usefulness of parenteral iron in order to avoid allogeneic transfusions in trochanteric hip fracture (THF).
A pseudo-experimental study was performed comparing a historic THF group (n = 104) with another group (n = 23) treated with parenteral iron (Venofer) (doses of 100 mg). Patients who had primary blood diseases or were receiving anticoagulation therapy were excluded. Age, gender, elapsed time, type of THF (international AO classification), surgical procedure, transfusion procedure and quantity, hemoglobin and hematocrit at days 0 and +2 (if a surgical procedure was not performed) and postoperatively were examined. We also analyzed the morbidity (post-surgical infection) and hospital stay and mortality rate at the first month.
We have not observed any adverse reactions upon iron administration. The iron group was transfused less times (39.1% vs. 56.7%) and had lower morbidity (infection) (20.3% vs. 35.4%) (p = 0.04), lower mortality (13% vs. 16.3%), less blood consumption (0.87 vs. 1.31 units) and less stay (13.7 vs. 14.3 days).
Parenteral administration of iron could be a safe and effective way to avoid or reduce allogeneic blood transfusions in THF patients. The reduction in the transfusional rate in the iron treated group is also accompanied by a reduction in the morbidity, infection rate, mortality rate and hospital stay.